LNP3693 / Lupin - LARVOL DELTA

A phase I dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma (ESMO 2025) - "Further, the best overall response of stable disease reported in 1 patient in 0.2 mg cohort indicates preliminary signal of efficacy with LNP3693. Conclusions LNP3693 was well tolerated with desirable safety, PK/PD and preliminary efficacy profile."

Clinical • Metastases • P1 data • Head and Neck Cancer • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • CXCL10 • IFNB1 • STING

Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025 (PRNewswire) - "The presentation, titled 'A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,' will be featured in the Investigational Immunotherapy session....The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors."

P1 data • Lymphoma • Solid Tumor